Cancer is a highly fatal disease that spreads throughout the world. Despite the availability of treatments such as surgery, chemotherapy, and immunotherapy, their effectiveness is limited and can lead to complications. It is crucial to develop advanced and efficient treatment strategies to detect and treat various types of cancer. Moreover, understanding the circadian regulation of immune responses, therapeutic efficacy, molecular and immunological mechanisms related to therapeutic strategies, and other elements associated with cancer progression, development, and metastasis is also of utmost importance.
The focus of the Research Topic "Molecular Mechanisms and Immunotherapeutic Targets in Nanomedicine-based Cancer Therapy" is to combine recent discoveries in cancer diagnosis and treatment with molecular and immunological regulations. Researchers and clinicians are encouraged to share their experiences and findings regarding the detection and treatment of various types of cancer, which could be significant in comprehending the molecular and immunological regulations in cancers and the relative influence on nanomedicines-based therapeutics as well as targeted or individualized therapeutic strategies. Manuscripts focusing on molecular regulations, immunological responses, nanomedicine-based therapeutic advancements or efficacy, and clinical interventions are encouraged. The contents may include, but are not limited to, the following subtopics:
1) Molecular regulations based on nanomedicine or nanotherapeutic approaches in cancer
2) Cancer treatment with nanomedicine or nanomaterials by targeting immunological responses or immune regulations in cancer
3) Targeted therapies in combination with immunotherapeutic approaches in cancer
4) Novel and/or potential therapeutic or treatment options based on molecular or immunological regulations in cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Cancer is a highly fatal disease that spreads throughout the world. Despite the availability of treatments such as surgery, chemotherapy, and immunotherapy, their effectiveness is limited and can lead to complications. It is crucial to develop advanced and efficient treatment strategies to detect and treat various types of cancer. Moreover, understanding the circadian regulation of immune responses, therapeutic efficacy, molecular and immunological mechanisms related to therapeutic strategies, and other elements associated with cancer progression, development, and metastasis is also of utmost importance.
The focus of the Research Topic "Molecular Mechanisms and Immunotherapeutic Targets in Nanomedicine-based Cancer Therapy" is to combine recent discoveries in cancer diagnosis and treatment with molecular and immunological regulations. Researchers and clinicians are encouraged to share their experiences and findings regarding the detection and treatment of various types of cancer, which could be significant in comprehending the molecular and immunological regulations in cancers and the relative influence on nanomedicines-based therapeutics as well as targeted or individualized therapeutic strategies. Manuscripts focusing on molecular regulations, immunological responses, nanomedicine-based therapeutic advancements or efficacy, and clinical interventions are encouraged. The contents may include, but are not limited to, the following subtopics:
1) Molecular regulations based on nanomedicine or nanotherapeutic approaches in cancer
2) Cancer treatment with nanomedicine or nanomaterials by targeting immunological responses or immune regulations in cancer
3) Targeted therapies in combination with immunotherapeutic approaches in cancer
4) Novel and/or potential therapeutic or treatment options based on molecular or immunological regulations in cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
